TP53 and acute myeloid leukemia: Previous studies have shown that inhibiting MDM2 has the potential to reduce leukemic cell growth and that antagonizing MDM2 can induce TP53-dependent apoptosis in AML cells, suggesting that this is a promising novel therapeutic strategy for AML patients (Kojima et al. 2005; Kandarpa et al. 2019; Ho et al. 2022).